SCHEMBL527160

SCHEMBL527160

O=C1N=C2C(=Cc3ccccc32)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.46
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
CDC25B P30305 3/20 0.34
CDC25A P30304 1/20 0.34
PTPRC P08575 5/20 0.32
PTPN1 P18031 4/20 0.32
PTPRF P10586 1/20 0.32
GLS O94925 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 2/20 0.31
BCHE P06276 2/20 0.31
POLB P06746 2/20 0.31
MAPT P10636 2/20 0.31
THRB P10828 2/20 0.31
CES1 P23141 2/20 0.31
RECQL P46063 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31410969 0.80 PTPRC (0.42) CDC25BPTPRCMEN1KMT2AHSD17B10
SCHEMBL261676 0.76 ABCG2 (0.62) ABCG2MEN1KMT2AHSD17B10KDM4E
SCHEMBL30019213 0.76 ABCG2 (0.62) ABCG2MEN1KMT2AHSD17B10KDM4E
SCHEMBL7464999 0.74 ABCG2 (0.55) ABCG2CDC25BCDC25AMEN1KMT2A
SCHEMBL2796799 0.72 ABCG2 (0.37) ABCG2
SCHEMBL29555333 0.70 ABCG2 (0.37) ABCG2CDC25BCDC25A
SCHEMBL29555624 0.70 PTPRC (0.42) ABCG2PTPRCPTPN1MEN1KMT2A
SCHEMBL7733305 0.69 ABCG2 (0.50) ABCG2HSD17B10ALDH1A1HPGDHIF1A
SCHEMBL9118090 0.69 ABCG2 (0.38) ABCG2DRD2DRD4CDC25BCDC25A
SCHEMBL3444897 0.68 CDC25B (0.57) CDC25BCDC25APTPRCPTPN1PTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074917-A1 Preparation and Uses of 7-Azaindenoisoquinolines PURDUE RESEARCH FOUNDATION 2025-03-06 US disclosed
CN-119497715-A Preparation and application of 7-aza-indeno isoquinoline 珀杜研究基金会 2025-02-21 CN disclosed
US-9598418-B2 Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 CADILA HEALTHCARE LIMITED (IN) 2017-03-21 US disclosed
EP-2938598-B1 SUBSTITUTED PHTHALAZIN-1(2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 CADILA HEALTHCARE LTD (IN) 2016-12-21 EP disclosed
US-20150291603-A1 SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 CADILA HEALTHCARE LIMITED (IN) 2015-10-15 US disclosed
EP-2598491-B1 SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS CADILA HEALTHCARE LTD (IN) 2015-09-02 EP disclosed
US-8871765-B2 Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors CADILA HEALTHCARE LIMITED (IN) 2014-10-28 US disclosed
EP-2598491-A1 SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS Cadila Healthcare Limited (IN) 2013-06-05 EP disclosed
US-20130137695-A1 SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2013-05-30 US disclosed
WO-2012014221-A1 SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2012-02-02 WO disclosed
EP-1868607-A4 ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORP (US) 2008-05-14 EP disclosed
EP-1868607-A2 ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF Inotek Pharmaceuticals Corporation (US) 2007-12-26 EP disclosed
US-20060287313-A1 Isoquinoline compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2006-12-21 US disclosed
WO-2006093666-A2 ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074917-A1 Preparation and Uses of 7-Azaindenoisoquinolines MYC, MYCBP, DNMT1 ABCG2 1098/4885DRD2 3857/4885DRD4 2629/4885
US-20130137695-A1 SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS PARP1, PARP2, PARP11 ABCG2 766/4885DRD2 3800/4885DRD4 4006/4885
US-20060287313-A1 Isoquinoline compounds and methods of use thereof GLS, PINK1, PARK7 ABCG2 1512/4885DRD2 489/4885DRD4 670/4885
US-20150291603-A1 SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 PARP1, PARP11, PARP2 ABCG2 58/4885DRD2 4523/4885DRD4 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.